Ge Yu-Zheng, Yu Peng, Jia Rui-Peng, Wu Ran, Ding Ai-Xing, Li Liang-Peng, Zhao Yan, Feng Yu-Ming, Gui Zan-Long, Liao Sheng
Department of Urology & Center of Renal Transplantation, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China.
Department of Urology & Center of Renal Transplantation, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China.
Transpl Immunol. 2014 Mar;30(2-3):76-83. doi: 10.1016/j.trim.2014.01.001. Epub 2014 Jan 28.
Transforming growth factor beta-1(TGFB1) is involved in the acute rejection (AR) episodes of solid organ transplant recipients. However, results from published studies on the association between donor/recipient TGFB1 +869T/C polymorphism and AR risk are conflicting and inconclusive.
PUBMED, EMBASE, CNKI and Wanfang Database were searched to identify eligible studies investigating the association between donor/recipient TGFB1 +869T/C polymorphism and AR risk. Statistical analysis was performed by using STATA 10.0.
A total of 29 studies were included. Overall, the donor TGFB1 +869T/C polymorphism was significantly associated with AR risk in heterozygote comparison (CT vs. TT: OR = 1.67, 95%CI, 1.17-2.39; P heterogeneity=0.285) and dominant model (CC vs.
TC/TT: OR = 1.47, 95%CI, 1.05-2.06; P heterogeneity=0.445). In addition, subgroup analysis revealed that CT variant (CT vs. TT: OR = 1.97, 95%CI, 1.20-3.25; P heterogeneity = 0.777) and CC/CT genotype (CC/CT vs. TT: OR = 1.72, 95%CI, 1.07, 2.78; P heterogeneity = 0.619) within donors contributed to higher risk of AR in recipients administrated with CsA or FK506, compared with those applied only CsA. On the other hand, no significant association between recipient TGFB1 +869T/C polymorphism and AR was detected in all genetic models.
This meta-analysis and systematic review suggested that donor TGFB1 +869T/C polymorphism was significantly associated with AR of solid organ transplant recipients, and especially among patients in CsA/FK 506 group compared with those in CsA group.
转化生长因子β-1(TGFB1)参与实体器官移植受者的急性排斥反应(AR)。然而,已发表的关于供体/受体TGFB1 +869T/C多态性与AR风险之间关联的研究结果相互矛盾且尚无定论。
检索PUBMED、EMBASE、中国知网和万方数据库,以确定研究供体/受体TGFB1 +869T/C多态性与AR风险之间关联的合格研究。使用STATA 10.0进行统计分析。
共纳入29项研究。总体而言,在杂合子比较(CT与TT:OR = 1.67,95%CI,1.17 - 2.39;P异质性 = 0.285)和显性模型(CC与TC/TT:OR = 1.47,95%CI,1.05 - 2.06;P异质性 = 0.445)中,供体TGFB1 +869T/C多态性与AR风险显著相关。此外,亚组分析显示,与仅应用环孢素(CsA)的受者相比,接受CsA或他克莫司(FK506)治疗的受者中,供体内的CT变异(CT与TT:OR = 1.97,95%CI,1.20 - 3.25;P异质性 = 0.777)和CC/CT基因型(CC/CT与TT:OR = 1.72,95%CI,1.07,2.78;P异质性 = 0.619)导致AR风险更高。另一方面,在所有遗传模型中均未检测到受体TGFB1 +869T/C多态性与AR之间存在显著关联。
这项荟萃分析和系统评价表明,供体TGFB1 +869T/C多态性与实体器官移植受者的AR显著相关,尤其是在CsA/FK506组患者中与CsA组患者相比。